Richmond Pharmacology presents �Improving Clinical Trial Design�at the BAPU 4th 2-yearly Symposium 2012

The Belgian Association of Phase 1 Units (BAPU) will host its 4th 2-yearly symposium this year in Antwerp, taking place 9th November 2012. The focus of this year�s meeting is modernising and innovation in early clinical drug development towards 2020.Founded in January 2005, BAPU represents the Belgian phase I clinical research units from both the pharmaceutical industry and academia. One of its primary objectives is to facilitate collaboration between Belgian phase I units as well as international phase I units and regulatory authorities.Invited on behalf of BAPU, Dr Ulrike Lorch�s presentation on Improving Clinical Trial Design will describe the benefit of adaptive design in First into Human and Early Phase Combination Studies, showing how its use, compared to conventional study designs, can lead to comprehensive time savings in early research programs.Click here to view full program and to registerWatch our latest presentation on Adaptive Study Design

Latest news

Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme

February 17, 2025
We are committed to embedding Environmental, Social, and Governance (ESG) principles into our clinical research operations to drive responsible and sustainable business growth...
Read more

Trial That Could Revolutionise Cardiac Safety Studies – Research Consortium Calls For Others To Join

February 10, 2025
The US-based Cardiac Safety Research Consortium has endorsed a project aimed at replacing the routine use of drugs...
Read more

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

April 7–11
Exploring advancements shaping the future of healthcare.
View event